Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000706143 | SCV000835177 | uncertain significance | Hyperkalemic periodic paralysis | 2018-05-31 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with SCN4A-related disease. This variant is present in population databases (rs753182664, ExAC 0.1%). This sequence change replaces glutamine with proline at codon 823 of the SCN4A protein (p.Gln823Pro). The glutamine residue is highly conserved and there is a moderate physicochemical difference between glutamine and proline. |
Fulgent Genetics, |
RCV000764143 | SCV000895128 | uncertain significance | Hypokalemic periodic paralysis, type 1; Potassium-aggravated myotonia; Paramyotonia congenita of Von Eulenburg; Hypokalemic periodic paralysis, type 2; Hyperkalemic periodic paralysis; Congenital myasthenic syndrome 16 | 2018-10-31 | criteria provided, single submitter | clinical testing |